SCAI is seeking your comments on the SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Best Practices for Optimal Techniques, Competence, Training and Organizational Recommendations.
The Society for Cardiovascular Angiography and Interventions is now accepting comments on the SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Best Practices for Optimal Techniques, Competence, Training and Organizational Recommendations. Anyone may submit comments, including SCAI members and non-member physicians and healthcare professionals, patients, caregivers, researchers, industry stakeholders, and insurance companies.
If you would like to submit a comment, please:
- Download the statement.
- Review the writing group disclosures.
- Complete the comment survey.
Feedback is requested by Wednesday, June 14, 2023.
You must complete the whole comments process in one sitting, as your progress cannot be saved until the end. The process will take between 5 and 15 minutes to complete depending on the number of comments you have to offer.
About the Statement
Despite the advent of medical therapy for hypertension, population blood pressure control remains suboptimal. Limitations of medical therapy include cost, adverse side effects, limited access, and poor adherence. Renal denervation (RDN) is a minimally invasive, endovascular procedure targeting sympathetic nerves adjacent to the renal arteries. Disruption of these nerves has been shown in sham-controlled, randomized trials to produce clinically meaningful and safe short-term reductions in blood pressure while registry data suggest that these results are durable. RDN may represent an alternative treatment or adjunct to medical therapy for hypertension.
In 2021, the Society for Cardiovascular Angiography and Interventions (SCAI) published an expert consensus roundtable statement cosponsored by SCAI and the National Kidney Foundation. This document focused on the historical progress of hypertension control, clinical trial data, the importance of multidisciplinary evaluation, and patient-centered treatment decision-making considerations for potential patients who may benefit from catheter-based renal denervation.
Pending US FDA approval, guidance on appropriate integration of RDN into clinical practice will be of paramount importance to ensure standardization of clinical protocols and optimization of procedural outcomes. This SCAI position statement will address patient selection, review optimal procedural and technical considerations, propose a roadmap for operator training and competency, and delineate institutional requirements for programmatic success.
Development of the statement is sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI).
About the Public Comment Period
SCAI develops evidence-based guidance through a rigorous process to help health care providers and patients make decisions, minimize inappropriate practice variation, promote effective resource use, improve clinical outcomes, and direct future research. For a detailed description of the development process and methodology, please refer to the SCAI Publications Committee Manual of Standard Operating Procedures.
Draft statements are made available for public comment before society approval and publication with the aim of engaging key stakeholders in a transparent and rigorous development effort. At the end the comment period, the writing group will review the feedback received and may revise the statement in response. Comments may also inform SCAI’s communication and implementation plan and future updates of the material. Individuals or organizations that provide comments will not typically be identified by name within the final published guidelines.